Granza Bio

Granza Bio is an early-stage biotechnology company reprogramming immunity for target-specific medicines. Founded in 2024 by Dr. Ashwin Nandakumar, Dr. Ashwin Jainarayanan, and Prof. Michael Dustin, the company builds on the discovery of "attack particles" — killing entities released by cytotoxic immune cells, characterized in Prof. Dustin's laboratory at the University of Oxford. Granza Bio is developing an engineered delivery-shell platform that directs therapeutic cargo to specific tissues, with the goal of advancing treatments for cancers, autoimmune disorders, and infections. The company raised $7.14M in seed funding co-led by Refactor Capital and Felicis, with participation from Pioneer Fund and Y Combinator. It is a research-stage life-sciences company and does not currently publish a public developer API, SDK, or developer portal; this profile is maintained in the API Evangelist network as a company record.

Granza Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Immunotherapy, Drug Delivery, and Life Sciences.

Granza Bio’s developer surface includes engineering blog and 3 more developer resources.

🌐 Visit website 📡 Source on GitHub
11.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyImmunotherapyDrug DeliveryLife SciencesOncologyTherapeutics

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 11.2/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.4 / 20
Commercial Clarity 2.1 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/granzabio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Granzabio Domain Security

TLSv1.3 · HSTS

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy

Company 2

The organization behind the API

Website
Website
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: granzabio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/granzabio.png
name: Granza Bio
description: Granza Bio is an early-stage biotechnology company reprogramming immunity for target-specific medicines. Founded
  in 2024 by Dr. Ashwin Nandakumar, Dr. Ashwin Jainarayanan, and Prof. Michael Dustin, the company builds on the discovery
  of "attack particles" — killing entities released by cytotoxic immune cells, characterized in Prof. Dustin's laboratory
  at the University of Oxford. Granza Bio is developing an engineered delivery-shell platform that directs therapeutic cargo
  to specific tissues, with the goal of advancing treatments for cancers, autoimmune disorders, and infections. The company
  raised $7.14M in seed funding co-led by Refactor Capital and Felicis, with participation from Pioneer Fund and Y Combinator.
  It is a research-stage life-sciences company and does not currently publish a public developer API, SDK, or developer portal;
  this profile is maintained in the API Evangelist network as a company record.
url: https://raw.githubusercontent.com/api-evangelist/granzabio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- felicis
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Immunotherapy
- Drug Delivery
- Life Sciences
- Oncology
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://granzabio.com
- type: Blog
  name: Newsroom
  url: https://www.granzabio.com/newsroom
- type: PrivacyPolicy
  url: https://www.granzabio.com/privacy-policy
- type: DomainSecurity
  url: security/granzabio-domain-security.yml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence